Nordic Life Science 1
T E X T b y M AL IN O T M ANI Robert Wessman, Fou
nder, Alvotech have entered into an exclusive THE RESEARCH ENVIRONMENTS of the Karolinska Institutet were previously, scattered across the campus, a green park area with red brick buildings dating from the 1930s. With Biomedicum, the Institute has gained a single unifying environment for future research, with ultra-flexibly equipped laboratories and office facilities that will act as a catalyst for cross-cutting collaboration between the various research and study environments. The new construction is not only intended to provide a building in the campus park but also to accommodate the park within the building. With a glass-covered green atrium the outdoor campus area is continued through the building, thereby reinforcing the social qualities of the green campus to the benefit of knowledgesharing and interdisciplinarity. The building’s openness is created with a transparent and inviting ground floor with access to the atrium, as well as a café and public exhibition space. This also forms new linkages through the park and thereby opens up the Karolinska Institutet towards both the city and the new planned university hospital, Nya Karolinska Solna (NKS), which will be directly adjacent. strategic partnership for the commercialization in the U.S. of five biosimilar product candidates. “This is not only a big moment for the biosimilar industry but also a very special moment for Alvotech, as we continue to join forces with leading global and regional partners around the world,” says Robert Wessman, Alvotech’s founder and Chairman. Alvotech will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercializing the products in the U.S. The originator products of these five candidates currently generate around $35 billion in U.S. sales. The agreement includes an upfront payment, with subsequent milestone payments over the next several years. Teva and Alvotech will share profit from the commercialization of the biosimilars. All other financial terms and product details remain confidential. NORDIC LIFE SCIENCE 9 PHOTO JEAN-BAPTISTE BÉRANGER